Sdpc.Jk

The company's capital structure is characterized by a high debt-to-equity ratio of 2.57, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.1, suggesting limited short-term liquidity cushion. The price-to-book ratio of 0.75 and price-to-tangible-book ratio of 0.75 indicate that the company's market value is below its book value, potentially signaling undervaluation or asset impairment concerns.

Profitability metrics show a return on equity (ROE) of 12.2%, which is relatively strong, but the return on assets (ROA) of 1.96% is weak, suggesting inefficient use of assets to generate returns. The operating margin, calculated as operating income of 113.5 billion IDR over revenue of 4.11 trillion IDR, is 2.76%, which is below the industry median for pharmaceuticals, indicating room for improvement in cost control and operational efficiency.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue concentration is not specified. Given the lack of segmental breakdown, it is unclear whether the company's operations are diversified across therapeutic areas or geographic regions. The absence of segmental data limits the ability to assess exposure to specific markets or product lines.

The company's growth trajectory is modest, with no specific revenue growth rates provided in the input data. The capital expenditure of -49.1 billion IDR suggests a reduction in investment in physical assets, which may indicate a focus on cost-cutting or a shift toward digital or service-based offerings. The free cash flow of 10.2 billion IDR is positive but relatively small compared to operating cash flow of 88.1 billion IDR, indicating some reinvestment in the business.

Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's high debt load and low liquidity may pose challenges in the event of a financial downturn or unexpected capital needs.

Recent events and filings are not detailed in the input data, but the company's financial snapshot indicates a stable but not robust financial position. The absence of recent earnings call transcripts or 10-K filings in the input data limits the ability to assess management's strategic direction or recent operational developments.